Biotech entity
European Commission is most often covered alongside ANKTIVA, which appears in 1 of these 2 stories. The 167-day window averages about 0.1 stories each week. They are less corroborated than the beat average, carrying 2.5 original sources each against 3.7 for the same window.
Last mentioned: Jul 12, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
European Commission is most often covered alongside ANKTIVA, which appears in 1 of these 2 stories. The 167-day window averages about 0.1 stories each week. They are less corroborated than the beat average, carrying 2.5 original sources each against 3.7 for the same window. Their average consequence score of 6 runs below the beat's 6.2 for that window. The clearest coverage concentration is fda-approval: 1 of 2 stories, with the rest divided among 1 other category. European Commission appears in 2 tracked Biotech stories published from February 18, 2026 through August 3, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 672 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering European Commission. Shared-story counts are live from our verified record — not editorial picks.
High Court grants permission for judicial review
Judge Cian Ferriter allows Emily Felix's challenge against the HSE and Minister for Health to proceed, citing arguable grounds regarding the delay.
NCPE pharmacoeconomic evaluation completed
The National Centre for Pharmacoeconomics delivers its assessment of Skyclarys' cost-effectiveness to the HSE.
HSE reimbursement application filed
Biogen submits a formal pricing and reimbursement application to the HSE to add Skyclarys to the public drug list.
European market authorisation
The European Commission grants centralised marketing authorisation for Biogen's Skyclarys (omaveloxolone) for patients over 16.
Diagnosis with Friedreich's ataxia
Emily Felix, then 12 years old, is diagnosed with the rare, progressive neuromuscular disease.
Biogen’s orphan drug for Friedreich’s ataxia, approved by the EMA since February 2024, remains mired in Irish reimbursement ambiguity, prompting a patient’s judicial review and highlighting the EU’s fragmented market access for novel therapies.
ImmunityBio (IBRX) shares rallied following the European Commission's marketing authorization of ANKTIVA for BCG-unresponsive non-muscle invasive bladder cancer. This milestone marks the first international expansion for the IL-15 superagonist, significantly broadening its global commercial reach.
Source: The Motley Fool · AOL.com
European Commission is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
